Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06451055
Other study ID # STUDY00007848
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2024
Est. completion date February 2025

Study information

Verified date June 2024
Source Emory University
Contact Sathish Thirunavukkarasu, PhD
Phone (404) 778-3771
Email sathish.thirunavukkarasu@emory.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the preliminary efficacy of a low-calorie diet (LCD) intervention in addressing the underlying pathophysiological abnormalities and improving fasting hyperglycemia among individuals with i-IFG. Additionally, it seeks to assess the feasibility and acceptability of the LCD intervention.


Description:

This proof-of-concept randomized controlled trial (RCT) will enroll 34 individuals aged 35-65 years with overweight or obesity and isolated impaired fasting glucose. Intervention participants will adhere to an 8-week low-calorie dietary (LCD) regimen (~1,320 kcal/day) comprising specific macronutrient proportions (55% carbohydrate, 13% fat, 25% protein, and 2% fiber). Control participants will maintain their habitual dietary habits and physical activity levels. Primary outcomes at 8 weeks include between-group changes in weight, fasting plasma glucose, indices of ß-cell function and hepatic insulin resistance, and alanine aminotransferase levels. Secondary outcomes are feasibility metrics (response rate, screening yield, enrollment rate, intervention compliance, cost, staff time, and retention rate) and intervention acceptability. Qualitative research will explore facilitators, barriers, acceptability, satisfaction, and participant experiences with the LCD intervention.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 34
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: 1. Aged 35 to 65 years 2. Overweight (body mass index (BMI) =25 to <29 kg/m² or =23 to <29 kg/m2 if Asian descent) or Obese (BMI =30 kg/m²) 3. Physically inactive (<150 minutes per week of moderate-intensity physical activity or <75 minutes per week of vigorous-intensity physical activity) 4. Prediabetes diagnosis or score =5 on the American Diabetes Association (ADA) risk tool Exclusion Criteria: 1. Diagnosed with type 1 or type 2 diabetes 2. Cardiovascular disease (myocardial infarction, stroke, angina, heart failure, or other cardiac conditions) 3. Chronic kidney disease 4. Chronic liver disease (e.g., cirrhosis) 5. Cancers 6. Acute inflammatory bowel disease, irritable bowel syndrome, celiac disease, chronic pancreatitis, or other disorders potentially causing malabsorption 7. Food allergies 8. Participation in weight loss programs in the past six months 9. Currently following a specific diet (e.g., ketogenic diet, Mediterranean diet) 10. Participation in any exercise programs in the past six months 11. Currently taking weight-loss medications or drugs known to affect glycemia (steroids and antipsychotics) 12. Previous bariatric surgery or plan to have bariatric surgery during the study period 13. Planning to relocate during the study period 14. Intending to fast during the study period for religious or other reasons 15. Pregnancy or planning to become pregnant during the study period 16. Breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Low-calorie diet
LCD diet is designed to provide ~1300 kcal/day with a macronutrient composition of 55% carbohydrate, 13% fat, 25% protein, and 2% fiber.
Routine dietary and physical activity habits
Participants will be asked to maintain their habitual dietary and physical activity habits.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Emory University

Outcome

Type Measure Description Time frame Safety issue
Primary Weight in kg Weight will be measured using a digital weighing scale (Welch Ally-Scale-Tronix, NY, USA) with an accuracy to the nearest 0.1 kg 4 and 8 weeks
Primary Fasting plasma glucose in mg/dl Will be analyzed by enzymatic assays 4 and 8 weeks
Primary Indices of ß-cell function Will be assessed using the Insulinogenic index (IGI) 4 and 8 weeks
Primary Indices of ß-cell function Will be assessed using the Oral disposition index (DIo) 4 and 8 weeks
Primary Indices of ß-cell function Will be assessed using the Homeostatic model assessment of ß-cell function (HOMA-B) 4 and 8 weeks
Primary Indices of hepatic insulin resistance Will be assessed using the Hepatic insulin resistance index (HIRI) 4 and 8 weeks
Primary Alanine aminotransferase (liver enzyme) in U/L Will be analyzed with colorimetric assays 4 and 8 weeks
Secondary Response rate Response rate is defined as the proportion of individuals responding to the invitation sent via the Epic database. Baseline
Secondary Screening yield Screening yield: Proportion of screened individuals meeting eligibility criteria. Baseline
Secondary Enrollment rate Enrollment rate: Proportion of eligible individuals who enroll in the study. Baseline
Secondary Resource utilization Resource utilization: Assessment of expenditures and staff time. Throughout the study period, an average of 10 weeks
Secondary Retention rate Retention rate: Proportion of enrolled participants who complete the study. 4 and 8 weeks
Secondary Intervention acceptability Intervention acceptability will be assessed using the Theoretical Framework of Acceptability questionnaire. Scores range from 7 to 35. Higher scores indicate better acceptability among participants. 4 and 8 weeks
Secondary Feasibility of intervention Will be assessed using the Feasibility of Intervention Measure questionnaire. Scores range from 4 to 20. Higher scores indicate better feasibility among participants. 4 and 8 weeks
Secondary Intervention appropriateness Will be assessed with the Intervention Appropriateness Measure questionnaire. Scores range from 4 to 20. Higher scores indicate better appropriateness among participants. 4 and 8 weeks
Secondary Facilitators, barriers, acceptability, satisfaction, and participant experiences with the the intervention Qualitative in-depth interviews 4 and 8 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06143345 - HIIT in Isolated IFG: A Proof-of-Concept Study N/A
Completed NCT00140647 - The Study of Atherosclerosis With Ramipril and Rosiglitazone Phase 3